Machine signal
Active cluster sell — 5 distinct insiders, $16.7M, window ends Sep 10, 2026.
Figures computed from official regulatory filings — .
Analysttarget 344.25 USD (+14%) · consensus 4.73/5 · 11 buy · 0 hold · 0 sell
Ownershipinsiders 2.34% · institutions 116.08% · short 15.8% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for LIGAND PHARMACEUTICALS INC only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
357 buys650 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Zimmermann Martine | Other | $34.3K | SEC |
| Zimmermann Martine | Sell | $342K | SEC |
| Reardon Andrew | Sell | $513.3K | Unusual size | SEC |
| Reardon Andrew | Sell | $110.7K | SEC |
| Reardon Andrew | Sell | $115.6K | SEC |
| Reardon Andrew | Sell | $605.6K | Unusual size | SEC |
| Reardon Andrew | Sell | $85.2K | SEC |
| Espinoza Octavio | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Espinoza Octavio | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Espinoza Octavio | Sell | $9.2M | Unusual size | SEC |
| Espinoza Octavio | Exercise | $230.1K | Unusual size | SEC |
| Espinoza Octavio | Exercise | $159.9K | Unusual size | SEC |
| Haas Jason | Exercise | $316.5K | Unusual size | SEC |
| Espinoza Octavio | Exercise | $410.3K | Unusual size | SEC |
| Espinoza Octavio | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Espinoza Octavio | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Espinoza Octavio | Exercise | $145.3K | Unusual size | SEC |
| Espinoza Octavio | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Espinoza Octavio | Exercise | $854.9K | Unusual size | SEC |
| Haas Jason | Sell | $2.1M | Unusual size | SEC |
| Haas Jason | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Reardon Andrew | Sell | $9.4K | SEC |
| Reardon Andrew | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Reardon Andrew | Sell | $119.8K | SEC |
| Reardon Andrew | Exercise | $261.4K | SEC |